1. Home
  2. VERU

as of 12-12-2025 3:31pm EST

$2.47
$0.09
-3.52%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.

Chart Type:
Time Range:
Founded: 1971 Country:
United States
United States
Employees: N/A City: MIAMI
Market Cap: 39.8M IPO Year: 1990
Target Price: $25.00 AVG Volume (30 days): 108.8K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.23 EPS Growth: N/A
52 Week Low/High: $2.11 - $14.20 Next Earning Date: 12-17-2025
Revenue: $16,886,419 Revenue Growth: 337.24%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

AI-Powered VERU Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 80.00%
80.00%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Veru Inc. News

VERU Breaking Stock News: Dive into VERU Ticker-Specific Updates for Smart Investing

All VERU News

Share on Social Networks: